Clinical trials: Epirubicin
NMIBC
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with…
- Trial name
- NCT07424287
- Testing
- SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection
- Where
- 2 sites in China
- Volunteers
- 236 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma
"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
The purpose of this study is to evaluate a novel neoadjuvant regimen for invasive breast carcinoma by using the MD Anderson residual cancer burden score.To prospectively evaluate the utility of the PET scan to guide the…
- Conditions
- Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma
- Trial name
- NACprotocol (NCT01641406)
- Testing
- Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
- Where
- Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Auxilio Mutuo Cancer Center
Breast Neoplasms, Cardiac Event
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast…
- Conditions
- Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity
- Trial name
- NCT03785704
- Testing
- Xinmailong Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Peripheral T-cell Lymphoma
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
This is single-arm phase I/II study designed to evaluate the safety and efficacy of golcadotinib in combination with the CHOP regimen for patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06739265
- Testing
- Golidocitinib plus CHOP
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking Union Medical College Hospital
Bladder Cancer
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Bladder cancer (BC), the second most common urological malignancy, is an important public health issue. One of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which…
- Trial name
- NCT01675219
- Testing
- white light TUR-BT, blue light TUR-BT, optimized MMC
- Where
- 10 sites in Finland
- Volunteers
- 400 people
- Sponsor
- Turku University Hospital
Breast Cancer
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Primary Objectives: Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer.
- Trial name
- NCT00050167
- Testing
- Paclitaxel, Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 603 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin
prospective evaluation of topoisomerase II alpha gene amplification and protein overexpression as markers predicting the efficacy of epirubicin in the primary treatment of breast cancer patients.
- Trial name
- TOP (NCT00162812)
- Testing
- Epirubicin
- Where
- Belgium
- Volunteers
- 338 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Metastases
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to…
- Trial name
- NCT00099281
- Testing
- YMB 1002
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- YM BioSciences
Breast Cancer
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
A Phase II study that evaluating the efficacy and safety of pembrolizumab in combination with chemotherapy as neoadjuvant therapy for triple-negative breast cancer in the Chinese population
- Trial name
- NCT05681728
- Testing
- Pembrolizumab, Paclitaxel, Epirubicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)
In the recent AGO-study, a dose-dense and dose-intensified sequence of Epirubicin - Paclitaxel - Cyclophosphamide has shown superior efficacy compared to a conventionally dosed sequence of Epirubicin / Cyclophosphamid and…
- Trial name
- NCT00196872
- Testing
- Epirubicine, Cyclophosphamide, Taxol
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Cardiac Toxicity
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
- Trial name
- NCT01093235
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pancreatic Cancer
Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PACT-17 (NCT01167738)
- Testing
- capecitabine, cisplatin, epirubicin
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Despite modern surgical and medical treatments, breast cancer can re-occur and lead 20% of patients to death. During the last 20 years, pre-clinical studies have shown that treatment failures may be due to the presence of a…
- Trial name
- NCT06452394
- Testing
- Doxycyclin
- Where
- 8 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Swiss Cancer Institute
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL), with high aggressiveness and mortality, is one of the top ten high-incidence tumors in the world and is among the ten most prevalent cancers worldwide with the fastest growing incidence.
- Conditions
- High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma
- Trial name
- NCT05164770
- Testing
- Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shandong Provincial Hospital
Oesophageal Carcinoma
Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus
This is a study to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using capecitabine and cisplatin as radio-sensitisers in patients…
- Trial name
- NCT00220129
- Testing
- Epirubicin, Cisplatin, Capecitabine, Surgical Resection
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-muscle Invasive Bladder Cancer
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
A multi-center, randomized, open-label, parallel-controlled Phase Ⅲ clinical trial to evaluate the clinical safety and efficacy of APL-1202 as a single-agent oral treatment versus intravesical instillation of Epirubicin…
- Trial name
- ASCERTAIN (NCT04736394)
- Testing
- APL-1202, Epirubicin Hydrochloride
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Breast Cancer Female NOS, Tubular Breast Cancer Stage II
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.
- Conditions
- Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Invasive Ductal Breast Cancer
- Trial name
- GeparX (NCT02682693)
- Testing
- Denosumab, nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 780 people
- Sponsor
- GBG Forschungs GmbH
Early Breast Cancer, Triple Negative Breast Cancer
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Phase II, randomized, Active-controlled open label trial for treatment of high risk, HR-/HER2- (triple negative) breast cancer, with two sequences of neoadjuvant chemotherapy on a background of pembrolizumab
- Trial name
- KEYPARTNER (NCT06371807)
- Testing
- Pembrolizumab injection
- Where
- 3 sites in Portugal
- Volunteers
- 20 people
- Sponsor
- Fundacao Champalimaud
Breast Cancer
Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy
In recent years, the incidence rate of breast cancer has remained high. In China, breast cancer is the malignant tumor with the highest incidence rate among women.
- Trial name
- NCT05636644
- Testing
- Taxol
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Mei Zhang
Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005584
- Testing
- bleomycin sulfate, ABVD regimen, BEACOPP regimen
- Where
- 121 sites in Belgium, France and 8 more
- Volunteers
- 1,649 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC